These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15683066)

  • 41. [Development and perspectives of community DOTS].
    Narita T; Kobayashi N
    Kekkaku; 2009 Apr; 84(4):187-201. PubMed ID: 19425394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Access to medicines by patients of the primary health care in the Brazilian Unified Health System.
    Álvares J; Guerra AA; Araújo VE; Almeida AM; Dias CZ; Ascef BO; Costa EA; Guibu IA; Soeiro OM; Leite SN; Karnikowski MGO; Costa KS; Acurcio FA
    Rev Saude Publica; 2017 Nov; 51(suppl 2):20s. PubMed ID: 29160463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ['Judicialization' of public health policy for distribution of medicines].
    Chieffi AL; Barata RB
    Cad Saude Publica; 2009 Aug; 25(8):1839-49. PubMed ID: 19649425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dar es Salaam perinatal care study: needs assessment for quality of care.
    Nyamtema AS; Urassa DP; Massawe S; Massawe A; Mtasiwa D; Lindmark G; van Roosmalen J
    East Afr J Public Health; 2008 Apr; 5(1):17-21. PubMed ID: 18669118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innovation and the WHO's essential medicines list: giving credit where credit is due.
    Wertheimer AI; Santella TM
    Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
    [No Abstract]   [Full Text] [Related]  

  • 47. A rapid assessment methodology for the evaluation of primary care organization and performance in Brazil.
    Macinko J; Almeida C; de Sá PK
    Health Policy Plan; 2007 May; 22(3):167-77. PubMed ID: 17400576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Do international model drug control laws provide for drug availability?
    University of Wisconsin Pain & Policy Studies Group
    J Pain Palliat Care Pharmacother; 2009; 23(2):145-52. PubMed ID: 19492215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Using national health policies to improve access to palliative care medications in the community.
    Rowett D; Ravenscroft PJ; Hardy J; Currow DC
    J Pain Symptom Manage; 2009 Mar; 37(3):395-402. PubMed ID: 18722748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The public production of medicines compared to the National Policy of Medicines and the burden of disease in Brazil.
    Figueiredo TA; Schramm JMA; Pepe VLE
    Cad Saude Publica; 2017 Sep; 33(9):e00179815. PubMed ID: 28977283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The global-local dilemma of a Ministry of Health experiences from Uganda.
    Jeppsson A; Birungi H; Ostergren PO; Hagström B
    Health Policy; 2005 Jun; 72(3):311-20. PubMed ID: 15862639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consumer satisfaction with community pharmacies in Warri, Nigeria.
    Oparah AC; Kikanme LC
    Res Social Adm Pharm; 2006 Dec; 2(4):499-511. PubMed ID: 17161808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A critical comparison between the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines (Rename).
    Coelho HL; Rey LC; Medeiros MS; Barbosa RA; Cruz Fonseca SG; Costa PQ
    J Pediatr (Rio J); 2013; 89(2):171-8. PubMed ID: 23642428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of the selection of medicines for the Brazilian primary health care.
    Karnikowski MGO; Galato D; Meiners MMMA; Silva EVD; Gerlack LF; Bós ÂJG; Leite SN; Álvares J; Guibu IA; Soeiro OM; Costa KS; Costa EA; Guerra AA; Acurcio FA
    Rev Saude Publica; 2017 Nov; 51(suppl 2):9s. PubMed ID: 29160450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Could the WHO model list of essential medicines do more for the safe and appropriate use of injections?
    Logez SM; Hutin YJ; Holloway K; Gray R; Hogerzeil HV
    J Clin Pharmacol; 2004 Oct; 44(10):1106-13. PubMed ID: 15342611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?
    Osorio-de-Castro CGS; Azeredo TB; Pepe VLE; Lopes LC; Yamauti S; Godman B; Gustafsson LL
    Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):402-412. PubMed ID: 29117642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Judicialization of access to medicines in Minas Gerais state, Southeastern Brazil.
    Machado MA; Acurcio Fde A; Brandão CM; Faleiros DR; Guerra AA; Cherchiglia ML; Andrade EI
    Rev Saude Publica; 2011 Jun; 45(3):590-8. PubMed ID: 21445458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence-based process for decision-making in the analysis of legal demands for medicines in Brazil.
    Figueiredo TA; Osorio-de-Castro CG; Pepe VL
    Cad Saude Publica; 2013 Nov; 29 Suppl 1():S159-66. PubMed ID: 25402244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The essentiality and rationality of the Brazilian national listing of essential medicines].
    Yamauti SM; Bonfim JR; Barberato-Filho S; Lopes LC
    Cien Saude Colet; 2017 Mar; 22(3):975-986. PubMed ID: 28301004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.